Impact of daily vitamin D3 supplementation on the risk of vitamin D deficiency with the interaction of rs2282679 in vitamin D binding protein gene (GC) among overweight and obese children and adolescents: A one-year randomized controlled trial

Golaleh Asghari; Emad Yuzbashian; Ali Nikparast; Leila Najd Hassan Bonab; Maryam Mahdavi; Maryam S Daneshpour; Farhad Hosseinpanah; Parvin Mirmiran

doi:10.3389/fnut.2022.1061496

Impact of daily vitamin D₃ supplementation on the risk of vitamin D deficiency with the interaction of rs2282679 in vitamin D binding protein gene (GC) among overweight and obese children and adolescents: A one-year randomized controlled trial

Front Nutr. 2022 Dec 12:9:1061496. doi: 10.3389/fnut.2022.1061496. eCollection 2022.

Authors

Golaleh Asghari^{1

2}, Emad Yuzbashian^{2

3}, Ali Nikparast¹, Leila Najd Hassan Bonab⁴, Maryam Mahdavi⁵, Maryam S Daneshpour⁴, Farhad Hosseinpanah⁵, Parvin Mirmiran²

Affiliations

¹ Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
² Nutrition and Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
³ Department of Agricultural, Food and Nutritional Sciences, University of Alberta, Edmonton, AB, Canada.
⁴ Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
⁵ Obesity Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Abstract

Background: The rs2282679 polymorphism in the vitamin D binding protein (DBP) gene may influence the response to vitamin D supplementation. Therefore, we examine the effect of 1-year vitamin D supplementation on vitamin D deficiency (VDD) with the interaction of rs2282679 polymorphism in overweight and obese children and adolescents.

Materials and methods: The participants (n = 300) were part of a randomized controlled trial who received a daily supplement of either 1,000 or 2,000 IU or four supplements of 1,000 IU weekly (equal to 600 IU daily) of vitamin D₃ for 12 months. Genotyping was performed using amplification refractory mutation system polymerase chain reaction (ARMS-PCR).

Results: The mean of 25(OH)D values at baseline for participants with the TT, TG, and GG genotypes were 15.4, 14.4, and 10.8 ng/mL, respectively, and were not different between the three genotype groups (P = 0.062). A significant reduction in VDD was observed after vitamin D supplementation with dosages of 1,000 or 2,000 IU compared to 600 IU. No significant association of genotypes with risk of VDD was observed in each intervention group after vitamin D supplementation, except, that individuals with TG genotype showed a higher risk of VDD compared to those with TT genotype in the 2,000 IU group after 6 months of supplementation [odds ratio (95% CI): 6.94; 1.30-37.02]. We observed no interaction between time duration, three genotypes, and dosages with serum 25(OH)D, calcium, phosphorus, alkaline phosphatase, and parathyroid hormone levels.

Conclusion: Response to vitamin D supplementation by three doses of 600, 1,000, and 2,000 IU could not be affected by rs2282679 polymorphism during 12 months in overweight and obese children and adolescents.

Keywords: children; deficiency; polymorphism; rs2282679; supplement; vitamin D.